Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples